Nektar Therapeutics
NKTR
214 hedge funds and large institutions have $376M invested in Nektar Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 68 increasing their positions, 73 reducing their positions, and 38 closing their positions.
45% more call options, than puts
Call options by funds: $48K | Put options by funds: $33K
0.25% less ownership
Funds ownership: 6.24% → 5.99% (-0.25%)
7% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 73
7% less funds holding
Funds holding: 230 → 214 (-16)
33% less capital invested
Capital invested by funds: $561M → $376M (-$185M)
34% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 38
Top Buyers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.95M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.19M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.28M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$2.91M |
| 5 |
BlackRock
New York
|
+$2.84M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.4M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.47M |
| 3 |
Primecap Management
Pasadena,
California
|
-$2.46M |
| 4 |
Morgan Stanley
New York
|
-$2.13M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.68M |
NKTR Hedge Fund Activity: Q4 2022 in Review
214 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2022, worth a combined $376M — down 33% from $561M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of NKTR and 25 opened new positions — a net loss of 13 holders — while 73 trimmed existing stakes and 68 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $4.95M. The largest seller was Wellington Management Group, exiting entirely with an estimated $36.4M sold.
- 214 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2022, down from 230 in Q3 2022.
- Funds reported $376M of Nektar Therapeutics stock for Q4 2022, down 33% quarter-over-quarter.
- 25 funds opened new Nektar Therapeutics positions in Q4 2022 and 38 closed out, a net change of -13 holders.
- The largest Nektar Therapeutics buyer in Q4 2022 was Jacobs Levy Equity Management, an estimated $4.95M added.
- The largest Nektar Therapeutics seller in Q4 2022 was Wellington Management Group, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2022.